A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naive Patients With Hepatitis C Virus Genotype 2 or 3

Clinical Medicine and Research - United States
doi 10.3121/cmr.2013.1176.a1-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Marshfield Clinic Research Foundation

Related search

A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Impact of Interleukin-28b Gene Polymorphism [Rs12979860] on Egyptian Patients Infected With Hepatitis C Virus Genotype-4

Eastern Mediterranean Health Journal
Medicine
2013English

The Cost-Effectiveness of Hepatitis C Treatments in Treatment Naïve Genotype 1 Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections

Gastroenterology
HepatologyGastroenterology
2016English

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis-C Virus Infection in Venezuela

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Cost-Effectiveness of Cyp2c19*2 Genotype Guided Selection of Clopidogrel or Ticagrelor in Hong Kong Chinese Patients With Acute Coronary Syndrome

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

A Randomized, Controlled Study of Peginterferon Lambda-1a/Ribavirin ± Daclatasvir for Hepatitis C Virus Genotype 2 or 3

SpringerPlus
Multidisciplinary
2016English

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy

Gastroenterology
HepatologyGastroenterology
2019English

Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial

The Lancet
Medicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy